BOSTON and NOIDA, India, Feb. 15, 2024 /CNW/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that ...
BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a ...
Pride India Awards Special Edition 2025 Indian Icon of Real Estate Excellence - NBR Group:From Foundations to Futures, Introducing NBR Soul of the Seasons ...
Noida (Uttar Pradesh) [India], October 25 (ANI/PRNewswire): Curadev's emphasis on education stems from its transformational effects on the individual and society at large. While education is of ...
New Delhi, Mar 23 () Global pharma and life sciences major Bayer and domestic drug discovery firm Curadev have signed a research collaboration and licence agreement to discover new drug candidates for ...
Curadev Announces Research Collaboration and Licensing Agreement to Develop Cancer Immunotherapeutic
NEW DELHI, India, April 20, 2015 -- Curadev Pharma Private Ltd. today announced that it has entered into a research collaboration and exclusive license agreement with Roche for the development and ...
LONDON, May 8, 2019 /PRNewswire/ -- Curadev today announced it has licensed its novel lead small molecule Stimulator of Interferon Genes (STING) agonist (referred to by Curadev as CRD5500) and ...
is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results